• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by MedTech Acquisition Corporation

    8/29/23 8:00:07 AM ET
    $MTAC
    Medical Specialities
    Health Care
    Get the next $MTAC alert in real time by email
    SC 13G 1 ea184373-13gunique_trisalu.htm SCHEDULE 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No.   )*

     

    TRISALUS LIFE SCIENCES, INC.

    (Name of Issuer)

     

    Common Stock

    (Title of Class of Securities)

     

    89680M101

    (CUSIP Number)

     

    August 10, 2023

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐Rule 13d-1(b)
    ☒Rule 13d-1(c)
    ☐Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    1

    NAME OF REPORTING PERSONS

     

    Unique Diamond Investments Limited

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     

    (a) ☐
    (b) ☐

     

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    British Virgin Islands

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5

    SOLE VOTING POWER

     

    1,546,569*

    6

    SHARED VOTING POWER

     

    0

    7

    SOLE DISPOSITIVE POWER

     

    1,546,569*

    8

    SHARED DISPOSITIVE POWER

     

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,546,569*

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    5.9%**

    12

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    CO

      

    *Represent 1,546,569 shares of common stock, par value $0.0001 per share (“Common Stock”) of the Issuer held directly by Unique Diamond Investments Limited. Unique Diamond Investment Limited is wholly owned by ORI Healthcare Fund, L.P. The general partner of ORI Healthcare Fund, L.P. is ORI Capital Inc., which is beneficially owned by Ms. SONG, Hong Fang.

     

    **Represents the percentage ownership based on 26,316,681 shares of Common Stock of the Issuer outstanding as of August 10, 2023 as set forth in the Current Report on Form 8-K, filed with the Securities and Exchange Commission on August 16, 2023.

     

    2

     

     

    1

    NAME OF REPORTING PERSONS

     

    ORI Healthcare Fund, L.P.

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     

    (a) ☐
    (b) ☐

     

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Cayman Islands

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5

    SOLE VOTING POWER

     

    1,546,569*

    6

    SHARED VOTING POWER

     

    0

    7

    SOLE DISPOSITIVE POWER

     

    1,546,569*

    8

    SHARED DISPOSITIVE POWER

     

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,546,569*

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    5.9%**

    12

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    PN

     

    *Represent 1,546,569 shares of Common Stock of the Issuer held directly by Unique Diamond Investments Limited. Unique Diamond Investment Limited is wholly owned by ORI Healthcare Fund, L.P. The general partner of ORI Healthcare Fund, L.P. is ORI Capital Inc., which is beneficially owned by Ms. SONG, Hong Fang.

     

    **Represents the percentage ownership based on 26,316,681 shares of Common Stock of the Issuer outstanding as of August 10, 2023 as set forth in the Current Report on Form 8-K, filed with the Securities and Exchange Commission on August 16, 2023.

     

    3

     

     

    1

    NAME OF REPORTING PERSONS

     

    ORI Capital Inc.

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     

    (a) ☐
    (b) ☐

     

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Cayman Islands

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5

    SOLE VOTING POWER

     

    1,546,569*

    6

    SHARED VOTING POWER

     

    0

    7

    SOLE DISPOSITIVE POWER

     

    1,546,569*

    8

    SHARED DISPOSITIVE POWER

     

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,546,569*

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    5.9%**

    12

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    CO

     

    *Represent 1,546,569 shares of Common Stock of the Issuer held directly by Unique Diamond Investments Limited. Unique Diamond Investment Limited is wholly owned by ORI Healthcare Fund, L.P. The general partner of ORI Healthcare Fund, L.P. is ORI Capital Inc., which is beneficially owned by Ms. SONG, Hong Fang.

     

    **Represents the percentage ownership based on 26,316,681 shares of Common Stock of the Issuer outstanding as of August 10, 2023 as set forth in the Current Report on Form 8-K, filed with the Securities and Exchange Commission on August 16, 2023.

     

    4

     

     

    1

    NAME OF REPORTING PERSONS

     

    SONG, Hong Fang

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     

    (a) ☐
    (b) ☐

     

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Hong Kong

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5

    SOLE VOTING POWER

     

    1,546,569*

    6

    SHARED VOTING POWER

     

    0

    7

    SOLE DISPOSITIVE POWER

     

    1,546,569*

    8

    SHARED DISPOSITIVE POWER

     

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,546,569*

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    5.9%**

    12

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IN

     

    *Represent 1,546,569 shares of Common Stock of the Issuer held directly by Unique Diamond Investments Limited. Unique Diamond Investment Limited is wholly owned by ORI Healthcare Fund, L.P. The general partner of ORI Healthcare Fund, L.P. is ORI Capital Inc., which is beneficially owned by Ms. SONG, Hong Fang.

     

    **Represents the percentage ownership based on 26,316,681 shares of Common Stock of the Issuer outstanding as of August 10, 2023 as set forth in the Current Report on Form 8-K, filed with the Securities and Exchange Commission on August 16, 2023.

     

    5

     

     

     

    Item 1(a). Name of Issuer:

     

    TriSalus Life Sciences, Inc.

     

    Item 1(b). Address of Issuer’s Principal Executive Offices:

     

    6272 W. 91st Ave., Westminster, Colorado 80031.

     

    Item 2(a). Name of Person Filing:

     

    1.Unique Diamond Investments Limited
    2.ORI Healthcare Fund, L.P.
    3.ORI Capital Inc.
    4.Ms. SONG, Hong Fang
    (the “Reporting Persons”)

     

    The Reporting Persons have agreed to jointly file this statement pursuant to Rule 13d-1(k). A copy of such agreement is attached as Exhibit 1 to this statement.

     

    Unique Diamond Investments Limited holds 1,546,569 shares of Common Stock of the Issuer. Unique Diamond Investment Limited is wholly owned by ORI Healthcare Fund, L.P. The general partner of ORI Healthcare Fund, L.P. is ORI Capital Inc., which is beneficially owned by Ms. SONG, Hong Fang.

     

    Item 2(b). Address of Principal Business Office or, if none, Residence:

     

    The address of the Reporting Persons is C/O Room Nos. 4727-4734, 47/F, Sun Hung Kai Centre, Wan Chai Hong Kong.

     

    Item 2(c). Citizenship:

     

    The information required by Item 2(c) is set forth in Item 2(a).

     

    Item 2(d). Title of Class of Securities:

     

    Common Stock, par value $0.0001 per share

     

    Item 2(e). CUSIP Number:

     

    89680M101

     

    Item 3. If this statement is filed pursuant to sections 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

     

    (b)☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

     

    (c)☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

     

    6

     

     

    (d)☐Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);

     

    (e)☐An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

     

    (f)☐An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

     

    (g)☐A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

     

    (h)☐A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

    (i)☐A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     

    (j)☐A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);

     

    (k)☐Group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____

     

    Item 4. Ownership:

     

    (a)Amount Beneficially Owned: 1,546,569.

     

    (b)Percent of Class: 5.9%

     

    (c)Number of shares as to which such person has:

     

    (i)sole power to vote or to direct the vote: 1,546,569

     

    (ii)shared power to vote or to direct the vote: None

     

    (iii)sole power to dispose or to direct the disposition of: 1,546,569

     

    (iv)shared power to dispose or to direct the disposition of: None

     

    Item 5. Ownership of Five Percent or Less of a Class:

     

    Not Applicable

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person:

     

    Not Applicable

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:

     

    Not Applicable

     

    Item 8. Identification and Classification of Members of the Group:

     

    Not Applicable

     

    Item 9. Notice of Dissolution of Group:

     

    Not Applicable

     

    Item 10. Certification:

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

    7

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: August 29, 2023

     

    Unique Diamond Investments Limited  
         
    /s/ SONG, Hong Fang  
    Name: SONG, Hong Fang  
    Title: Director  
         
    ORI Healthcare Fund, L.P.  
         
    /s/ SONG, Hong Fang  
    Name: SONG, Hong Fang  
    Title: Director  
         
    ORI Capital Inc.  
         
    /s/ SONG, Hong Fang  
    Name: SONG, Hong Fang  
    Title: Director  
         
    SONG, Hong Fang  
         
    /s/ SONG, Hong Fang  
    SONG, Hong Fang  

     

    8

     

     

    Exhibit Index

     

    Exhibit 
    1Joint Filing Agreement

     

     

    9

     

    Get the next $MTAC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MTAC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MTAC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    TriSalus Life Sciences Completes Merger with MedTech Acquisition Corporation

    Advances TriSalus' Platform Focused on Improving Outcomes for Patients with Liver and Pancreatic Cancer Expected to Advance Technology Development and Sales Growth Advancing SD-101 Into Phase 2 Clinical Trial in Uveal Melanoma, Phase 1 Trial in Pancreatic Cancer and Continuing Clinical Trials in HCC and Cholangiocarcinoma Provides Cash Runway through Mid-2024 to Fund Key Milestones TriSalus' Common Stock Expected to Begin Trading on the Nasdaq under Symbol "TLSI" on August 11, 2023 TriSalus Life Sciences® Inc., (TriSalus or the Company), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tu

    8/10/23 4:05:00 PM ET
    $MTAC
    Medical Specialities
    Health Care

    MedTech Acquisition Corporation Adjourns Special Meeting of Stockholders

    MedTech Acquisition Corporation (NASDAQ:MTAC) ("MedTech" or the "Company") today announced that it convened and then adjourned, without conducting any business, its special meeting of stockholders (the "Special Meeting"). The Special Meeting is being held to vote on certain proposals related to the proposed business combination (the "Business Combination") with TriSalus Life Sciences ("TriSalus"). The Special Meeting has been adjourned until 11:00 a.m. Eastern Time on August 8, 2023. The Special Meeting will still be held virtually via webcast, and stockholders may attend and participate online by visiting https://www.cstproxy.com/medtechacquisition/sm2023. Participants will be able to li

    8/2/23 5:00:00 PM ET
    $MTAC
    Medical Specialities
    Health Care

    TriSalus Life Sciences Presents Additional Data for SD-101 Delivered by the Proprietary PEDD™ Method with the TriNav™ Device for Uveal Melanoma Liver Metastases at the ASCO 2023 Annual Meeting

    New data from PERIO-01 clinical trial indicates PEDD™ method resulted in modulation of the tumor microenvironment and decreased circulating tumor DNA (ctDNA) levels TriSalus Life Sciences® Inc., (TriSalus or the Company), an oncology company in the process of going public through a business combination transaction (the Business Combination) with MedTech Acquisition Corporation (NASDAQ:MTAC) (MedTech or MTAC), today announced additional Phase 1 clinical data presented at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting taking place in Chicago, Illinois, from June 2-6, 2023. TriSalus' ongoing Phase 1 Pressure-Enabled Regional Immuno-Oncology (PERIO-01) (NCT04935229) cl

    6/12/23 7:00:00 AM ET
    $MTAC
    Medical Specialities
    Health Care

    $MTAC
    SEC Filings

    View All

    SEC Form 424B3 filed by MedTech Acquisition Corporation

    424B3 - TriSalus Life Sciences, Inc. (0001826667) (Filer)

    1/25/24 5:23:14 PM ET
    $MTAC
    Medical Specialities
    Health Care

    SEC Form 424B3 filed by MedTech Acquisition Corporation

    424B3 - TriSalus Life Sciences, Inc. (0001826667) (Filer)

    1/25/24 5:21:58 PM ET
    $MTAC
    Medical Specialities
    Health Care

    MedTech Acquisition Corporation filed SEC Form 8-K: Leadership Update

    8-K - TriSalus Life Sciences, Inc. (0001826667) (Filer)

    1/25/24 5:19:33 PM ET
    $MTAC
    Medical Specialities
    Health Care

    $MTAC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Szela Mary T was granted 84,899 shares, increasing direct ownership by 30% to 364,862 units (SEC Form 4)

    4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

    2/14/24 6:44:45 PM ET
    $MTAC
    Medical Specialities
    Health Care

    Marshak Richard was granted 14,752 shares, increasing direct ownership by 118% to 27,251 units (SEC Form 4)

    4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

    2/14/24 6:42:18 PM ET
    $MTAC
    Medical Specialities
    Health Care

    Cox Bryan F. was granted 14,752 shares, increasing direct ownership by 21% to 86,696 units (SEC Form 4)

    4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

    2/14/24 6:39:58 PM ET
    $MTAC
    Medical Specialities
    Health Care

    $MTAC
    Leadership Updates

    Live Leadership Updates

    View All

    TriSalus Life Sciences Appoints James Alecxih to Lead Device Technology Business

    TriSalus Life Sciences®, Inc. ("TriSalus" or the "Company"), an oncology company in the process of going public through a business combination transaction (the "Business Combination") with MedTech Acquisition Corporation (NASDAQ:MTAC) ("MedTech" or "MTAC"), today announced that James "Jim" Alecxih has joined the Company in the newly created role of President, Device Technology Business. Mr. Alecxih brings to TriSalus more than 30 years of experience in product development, launch and marketing strategies. His responsibilities will include overseeing the growth and development of TriSalus' TriNav® Infusion System ("TriNav®"), including device engineering, device quality, sales, marketing, a

    2/21/23 7:00:00 AM ET
    $MTAC
    Medical Specialities
    Health Care

    $MTAC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by MedTech Acquisition Corporation

    SC 13G - TriSalus Life Sciences, Inc. (0001826667) (Subject)

    8/29/23 8:00:07 AM ET
    $MTAC
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by MedTech Acquisition Corporation

    SC 13G - TriSalus Life Sciences, Inc. (0001826667) (Subject)

    8/23/23 12:02:13 PM ET
    $MTAC
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by MedTech Acquisition Corporation

    SC 13G - TriSalus Life Sciences, Inc. (0001826667) (Subject)

    8/22/23 8:15:18 AM ET
    $MTAC
    Medical Specialities
    Health Care